DIGNICAP CLINICAL TRIAL LAUNCHED AT BEIJING UNIVERSITY CANCER HOSPITAL

Study to examine scalp cooling to reduce hair loss from chemotherapy in cancer patients

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, is partnering with Beijing University Cancer Hospital and Konica Minolta in a clinical trial to assess the efficacy of scalp cooling for chemotherapy-induced hair loss in women with breast cancer.

Dr. Tao Ouyang, Chairman of Breast Center of Beijing University Cancer Hospital will lead the study which includes 256 patients at Beijing University Cancer Hospital over the course of approximately six months.

“This is a very important first step in our commitment to bring DigniCap to the Asian market in conjunction with our distribution partner Konica Minolta,” said William Cronin, Chief Executive Officer of Dignitana AB. “As of yet there is no data from a clinical study of scalp cooling with an exclusively Asian population. Beijing Cancer Hospital is a leading cancer treatment facility in Asia and we are eager to work with them in this milestone study.”

Konica Minolta, a Japanese multinational company headquartered in Tokyo, is Dignitana’s distribution partner in Asia and a natural choice as a partner to bring this product to Asia. With a large and growing presence in healthcare, the DigniCap product is a logical extension of their growing portfolio of healthcare products. The DigniCap Scalp Cooling System has had clearance from the U.S. Food and Drug Administration since 2015.

This advancement for Chinese cancer care comes at a time of rapid transformation for the country’s public health landscape with prevalence of cancer on the rise. Today, breast cancer is the most common cancer malignancy among Chinese women with 187,213 new cases per year and that number increasing in frequency by 2 to 3 percent each year. The sharp increase has triggered an urgency to develop prevention, treatment and quality of life cancer care methods.

Until the creation of scalp cooling hair loss was deemed an inevitable side effect of chemotherapy and it continues to serve as an unwelcome reminder of the disease to cancer patients. An estimated 10 percent of female patients decline prescribed chemotherapy out of fear of losing their hair, making greater accessibility to scalp cooling a vital component of cancer care.

This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 1100 CET on 14 October 2018.

For more information contact:
William Cronin, CEO, Dignitana AB bill.cronin@dignitana.com +1 469-917-5555
Mikael Wahlgren, Deputy Managing Director, Dignitana AB mikael.wahlgren@dignitana.com +46 709 33 72 20

About Dignitana AB (publ)
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize
hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank is Certified Adviser. Learn more at www.dignitana.se and www.dignicap.com.